Long-Term Impact of Subclinical Hypothyroidism on Cardiovascular Outcomes in Adults: A Meta-Analysis of Cohort and Observational Studies

Abali Wandala; Nana Akuoko- Frimpong; Marium Nadeem Khan; Hussein Khalid Mamdooh; Abdullah Ghaith Alshaharli; Sufyan Mustafa; Muhammad Bilal Akbar

doi:10.70749/ijbr.v3i4.1034

Authors

Abali Wandala Universidad Adventista del plata, Entre-Rios, Parana, Argentina
Nana Akuoko- Frimpong Ghana Health Service, Kumasi
Marium Nadeem Khan Shifa College of Medicine, Islamabad, Pakistan.
Hussein Khalid Mamdooh National University of Science and Technology, Oman.
Abdullah Ghaith Alshaharli National University of Science and Technology, Oman.
Sufyan Mustafa Dow University of Health Sciences, Karachi.
Muhammad Bilal Akbar Department of Psychiatry, Tallaght University Hospital, Dublin, Ireland.

DOI:

https://doi.org/10.70749/ijbr.v3i4.1034

Keywords:

Subclinical Hypothyroidism, Cardiovascular Outcomes, Coronary Heart Disease, TSH, Meta-Analysis

Abstract

Background: Subclinical hypothyroidism (SCH), defined by elevated thyroid-stimulating hormone (TSH) levels with normal free thyroxine (FT4), has been increasingly linked to cardiovascular disease. However, evidence remains mixed regarding its long-term impact on coronary outcomes. Objective: To evaluate the association between subclinical hypothyroidism and the risk of coronary heart disease (CHD) events, cardiovascular mortality, and all-cause mortality in adults using data from cohort and observational studies. Methods: A systematic search was conducted across PubMed, Scopus, Embase, and Web of Science from 2015 to 2024. Eligible studies included prospective cohorts reporting cardiovascular outcomes in adults with SCH versus euthyroid controls. Pooled hazard ratios (HRs) and relative risks (RRs) were calculated using a random-effects model. Subgroup analysis was conducted based on TSH levels (<10 mIU/L vs. ≥10 mIU/L). Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Results: Three high-quality cohort studies involving 60,047 participants were included. SCH was significantly associated with an increased risk of CHD events (HR/RR = 1.20; 95% CI: 1.02–1.41; p = 0.03). The association with CHD mortality (HR/RR = 1.18; 95% CI: 0.97–1.43) and total mortality (HR/RR = 1.12; 95% CI: 0.99–1.26) was not statistically significant. Subgroup analysis revealed that individuals with TSH ≥10 mIU/L had a markedly increased CHD risk (HR/RR = 1.89; 95% CI: 1.28–2.80; p = 0.002). Conclusion: Subclinical hypothyroidism, particularly at higher TSH levels (≥10 mIU/L), is associated with an increased risk of coronary heart disease events. While associations with mortality were non-significant, the observed trends highlight the need for closer monitoring and targeted intervention strategies in patients with elevated TSH. Further large-scale studies are warranted to establish causality and optimize clinical management.

Downloads

Download data is not yet available.

References

Rodondi, N., Aujesky, D., Vittinghoff, E., Cornuz, J., & Bauer, D. C. (2006b). Subclinical Hypothyroidism and the Risk of Coronary Heart Disease: A Meta-Analysis. The American Journal of Medicine, 119(7), 541–551. https://doi.org/10.1016/j.amjmed.2005.09.028

Suh, S., & Kim, D. K. (2015). Subclinical hypothyroidism and cardiovascular disease. Endocrinology and Metabolism, 30(3), 246. https://doi.org/10.3803/enm.2015.30.3.246

Inoue, K., Ritz, B., Brent, G. A., Ebrahimi, R., Rhee, C. M., & Leung, A. M. (2020). Association of subclinical hypothyroidism and cardiovascular disease with mortality. JAMA Network Open, 3(2), e1920745. https://doi.org/10.1001/jamanetworkopen.2019.20745

Ettleson, M. D. (2023). Cardiovascular outcomes in subclinical thyroid disease: an update. Current Opinion in Endocrinology Diabetes and Obesity. https://doi.org/10.1097/med.0000000000000818

Biondi, B., & Cooper, D. S. (2007b). The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews, 29(1), 76–131. https://doi.org/10.1210/er.2006-0043

Rodondi, N., Elzen, W. P. J. D., Bauer, D. C., Cappola, A. R., Razvi, S., Walsh, J. P., Åsvold, B. O., Iervasi, G., Imaizumi, M., Collet, T., Bremner, A., Maisonneuve, P., Sgarbi, J. A., Khaw, K., Vanderpump, M. P. J., Newman, A. B., Cornuz, J., Franklyn, J. A., Westendorp, R. G. J., . . . Collaboration, F. T. T. S. (2010d). Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA, 304(12), 1365. https://doi.org/10.1001/jama.2010.1361

Ochs, N., Auer, R., Bauer, D. C., Nanchen, D., Gussekloo, J., Cornuz, J., & Rodondi, N. (2008c). Meta-analysis: Subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Annals of Internal Medicine, 148(11), 832. https://doi.org/10.7326/0003-4819-148-11-200806030-00225

Singh, S., Duggal, J., Molnar, J., Maldonado, F., Barsano, C. P., & Arora, R. (2007b). Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: A meta-analysis. International Journal of Cardiology, 125(1), 41–48. https://doi.org/10.1016/j.ijcard.2007.02.027

Zhao, S., Zhang, B., Han, Y., Guan, J., Fang, W., Zhang, H., & Wang, A. (2023). Increased 10-year cardiovascular disease risk in depressed patients with coexisting subclinical hypothyroidism. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1185782

Sue, L. Y., & Leung, A. M. (2020). Levothyroxine for the treatment of subclinical hypothyroidism and cardiovascular disease. Frontiers in Endocrinology, 11. https://doi.org/10.3389/fendo.2020.591588

Biondi, B., & Cooper, D. S. (2008). The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews, 29(1), 76–131. https://doi.org/10.1210/er.2006-0043

Ochs, N., Auer, R., Bauer, D. C., Nanchen, D., Gussekloo, J., Cornuz, J., & Rodondi, N. (2008). Meta-analysis: Subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Annals of Internal Medicine, 148(11), 832–845. https://doi.org/10.7326/0003-4819-148-11-200806030-00225

Razvi, S., Ingoe, L., Keeka, G., Oates, C., McMillan, C., & Weaver, J. U. (2007). The beneficial effect ofl-Thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. The Journal of Clinical Endocrinology & Metabolism, 92(5), 1715–1723. https://doi.org/10.1210/jc.2006-1869

Rodondi, N., Elzen, W. P. J. D., Bauer, D. C., Cappola, A. R., Razvi, S., Walsh, J. P., Åsvold, B. O., Iervasi, G., Imaizumi, M., Collet, T., Bremner, A., Maisonneuve, P., Sgarbi, J. A., Khaw, K., Vanderpump, M. P. J., Newman, A. B., Cornuz, J., Franklyn, J. A., Westendorp, R. G. J., . . . Collaboration, F. T. T. S. (2010c). Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA, 304(12), 1365. https://doi.org/10.1001/jama.2010.1361

Singh, S., Duggal, J., Molnar, J., Maldonado, F., Barsano, C. P., & Arora, R. (2007). Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: A meta-analysis. International Journal of Cardiology, 125(1), 41–48. https://doi.org/10.1016/j.ijcard.2007.02.027

Rodondi, N., Elzen, W. P. J. D., Bauer, D. C., Cappola, A. R., Razvi, S., Walsh, J. P., Åsvold, B. O., Iervasi, G., Imaizumi, M., Collet, T., Bremner, A., Maisonneuve, P., Sgarbi, J. A., Khaw, K., Vanderpump, M. P. J., Newman, A. B., Cornuz, J., Franklyn, J. A., Westendorp, R. G. J., . . . Collaboration, F. T. T. S. (2010). Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA, 304(12), 1365. https://doi.org/10.1001/jama.2010.1361

Rodondi, N., Newman, A. B., Vittinghoff, E., De Rekeneire, N., Satterfield, S., Harris, T. B., & Bauer, D. C. (2005). Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Archives of Internal Medicine, 165(21), 2460. https://doi.org/10.1001/archinte.165.21.2460

Walsh, J. P., Bremner, A. P., Bulsara, M. K., O’Leary, P., Leedman, P. J., Feddema, P., & Michelangeli, V. (2005). Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Archives of Internal Medicine, 165(21), 2467. https://doi.org/10.1001/archinte.165.21.2467